Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Dec 25;72(25):3274-3284.
doi: 10.1016/j.jacc.2018.09.078.

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial

Cecilia C Low Wang  1 , Juuso I Blomster  2 , Gretchen Heizer  3 , Jeffrey S Berger  4 , Iris Baumgartner  5 , F Gerry R Fowkes  6 , Peter Held  7 , Brian G Katona  8 , Lars Norgren  9 , W Schuyler Jones  3 , Renato D Lopes  3 , Jeffrey W Olin  10 , Frank W Rockhold  3 , Kenneth W Mahaffey  11 , Manesh R Patel  3 , William R Hiatt  12 ; EUCLID Trial Executive Committee and Investigators
Affiliations
Free article
Randomized Controlled Trial

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial

Cecilia C Low Wang et al. J Am Coll Cardiol. .
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Coll Cardiol. 2019 Jul 16;74(2):264-269. doi: 10.1016/j.jacc.2019.06.001. J Am Coll Cardiol. 2019. PMID: 31296300 No abstract available.

Abstract

Background: Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD) on contemporary management.

Objectives: The authors sought to assess the risk of cardiovascular and limb events in patients with PAD and diabetes as compared with those with PAD alone.

Methods: In the EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) trial, 13,885 patients with symptomatic PAD were evaluated with a primary endpoint of an adjudicated composite of major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, ischemic stroke) followed over a median of ∼30 months. The diabetes subgroup was analyzed compared with the subgroup without diabetes, and further examined for diabetes-specific factors such as glycosylated hemoglobin (HbA1c) that might affect risk for major cardiovascular and limb outcomes.

Results: A total of 5,345 patients (38.5%) had diabetes; the majority (n = 5,134 [96.1%]) had type 2 diabetes. The primary endpoint occurred in 15.9% of patients with PAD and diabetes as compared with 10.4% of those without diabetes (absolute risk difference 5.5%; adjusted hazard ratio: 1.56; 95% confidence interval [CI]: 1.41 to 1.72; p < 0.001). Every 1% increase in HbA1c was associated with a 14.2% increased relative risk for MACE (95% CI: 1.09 to 1.20; p < 0.0001).

Conclusions: Patients with PAD and diabetes are at high risk for cardiovascular and limb ischemic events, even on contemporary therapies. Every 1% increase in HbA1c was associated with a 14.2% increased relative risk for MACE (95% CI: 1.09 to 1.20; p < 0.0001). (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

Keywords: P2Y(12) inhibitor; antithrombotic; cardiovascular; diabetes; limb amputation; peripheral artery disease.

PubMed Disclaimer

Comment in

Publication types

MeSH terms

Associated data